Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry describes a novel antisense noncoding transcript located opposite to the RBPJ gene. Antisense transcripts are RNA molecules transcribed from the strand opposite to a protein-coding gene and can regulate the expression of their sense partner gene, in this case, RBPJ, by mechanisms such as transcriptional interference, RNA duplex formation, modulation of chromatin state, and effects on transcript stability or translation[4][7]. There is no standardized functional characterization for this specific transcript, and it is not recognized as a conventional therapeutic target such as a receptor, enzyme, or transporter. Instead, it may play a regulatory role influencing the transcriptional dynamics of RBPJ. RBPJ itself is a well-characterized transcription factor central to Notch signaling pathways, but this antisense transcript’s biological significance is unclear and not clinically actionable at present[1][6][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to RBPJ.